Synbiotic Supplement
Phase 2Small molecule
Synbiotic Supplement is one of 56 small molecule programs targeting Gingivitis. It is currently in Phase 2.
2
Indications
2
Total Trials
0
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
583 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1Celexa
AbbViePreclinical
Resotran
TakedaPreclinical
Ozempic
Novo NordiskPreclinical
Zocor
OOrganon and Co
Preclinical
Ibrance
PfizerPreclinical
Depakote
AbbViePreclinical
Lunesta
Akero TherapeuticsPreclinical
Synbiotic Supplement
SSheppard Pratt Health System
Phase 2
Catapres
Boehringer IngelheimPreclinical
Compazine
GGlaxo Dba Glaxosmithkline
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Synbiotic Supplement. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSheppard Pratt Health System